Opioid Induced Constipation Treatment Market Current Industry Trend, Latest Development, Growth Estimation, Analysis by Size, Share, Global Demand Till 2026

Opioids are medications that work on opioid receptors in order to generate morphine-like effects. These are mainly used therapeutically to relieve pain and are often abused by individuals addicted to them. Opioids include opiates, a conventional name that points to drugs that are derivatives of opium, including morphine. Constipation means bowel actions that are sporadic or hard to go by.

Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/202

The fecal matter is often dry and hard. Some of the other symptoms include bloating, abdominal pain, and feeling the same as if the person has not passed bowels completely. Difficulties from constipation include anal fissure, fecal impaction, or hemorrhoids. Opioid-induced constipation is one of the most prevalent adverse effects connected with long-time use of opioids, which have a detrimental impact on the quality of life of the individual. The emblematic symptoms related to opioid-induced constipation are feeling hard and dry stools, distention and bulged abdomen, lethargy, loss of appetite, and painful defecation. Increasing consumption of opioids for several maladies is in turn leading to increasing prevalence of opioid-induced constipation, and as a result fueling growth of the opioid induced constipation treatment market. The fresh approval of medicines for treatment of opioid-induced constipation has led to emergence of various therapeutic approaches.

According to a report by the National Center for Biotechnology Information, chronic pain is a persistent pain that lingers for 3 months or more. The occurrence of chronic pain in the population is 10–15%. In individuals with chronic non-cancer pain, the commonness of opioid induced constipation varies from 41% to 81%. The common sign for opioid use in non-cancer pain is musculoskeletal pain such as degenerative joint disease, headache back pain, and fibromyalgia. In the current scenario, around 4% of adults in the U.S. undergo chronic opioid therapy. The Centers for Disease Control and Prevention (CDC) projected that excessive and unregulated prescription of opioids by healthcare providers is one of the key reasons for opioid-related overdose. Around 90% of individuals suffering from moderate to severe pain are prescribed opioids.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/202

Opioid-induced constipation treatment market Taxonomy

On the basis of method of administration, the global opioid-induced constipation treatment market is classified into:

• Subcutaneous Injection
• Oral

On the basis of drug, the global opioid-induced constipation treatment market is classified into:

• Lubiprostone
• Naloxegol
• Docusate Sodium
• Methylnaltrexone Bromide
• Others

On the basis of distribution channel, the global opioid-induced constipation market is classified into:

• Hospital Pharmacies
• Independent Pharmacies
• Others

Rising number of patients using illegal medicines and deferred use of opioids in the therapy of chronic pain are some of the key factors driving growth of the opioid induced constipation (OIC) treatment market. Moreover, it has been observed that the untapped market for advantageous, successful and safe therapeutic solutions in OIC drugs is extensive and developing at a fast pace, especially in developed regions.

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/opioid-induced-constipation-treatment-market-202

Increasing prevalence of opioid induced constipation and increase in chronic non-cancer pain to drive growth of overall opioid induced constipation treatment market

Prevalence of opioid induced constipation is rising considerably. According to the American Academy of Pain Medicine (AAPM), around 100 million patients in the U.S. suffered from opioid induced constipation in 2013. Furthermore, AAPM also estimated that the number of occurrences would rise, owing to increase in the number of individuals taking opioid drugs. There is growing responsiveness towards the availability of a large array of opioid drugs. This is expected to encourage patients to resort to the use of these drugs to treat chronic pain. The rising number of individuals suffering from opioid induced constipation, particularly in the North America, is projected to drive the market growth over the forecast period. The regional market is projected to grow at a considerable rate due to the presence of a large number of people who use opioid drugs. This is owing to high prevalence of disease associated with chronic pain in this region.

Some of the major companies operating in the opioid-induced constipation treatment market are Daewoong Co. Ltd., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Cosmo Pharmaceuticals, AstraZeneca plc, Abbott Laboratories, Valeant Pharmaceuticals, C.B. Fleet Company, Inc., and Bayer AG.

Key Developments

1. Key players in the market are focused on various growth strategies such as obtaining product approvals from regulatory authorities in order to expand their product portfolio. For instance, in March 2017, Shionogi & Co., Ltd received approval for Symproic (naldemedine) from the U.S. Food and Drugs Administration (FDA). Symproic is indicated for adults suffering from opioid-induced constipation.
2. Key players in the market are focused on various business strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in December 2018, Shionogi BV, the European subsidiary of Shionogi & Co., Ltd, received approval for Symproic (naldemedine) from European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP). Symproic is indicated for treatment of opioid-induced constipation in adults.
3. Major companies in the market are focused on various growth strategies such as merger and acquisitions, in order gain a competitive edge in the market. For instance, in December 2017, Mallinckrodt plc, a pharmaceutical company, acquired Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, which will include commercial and development assets. Under this acquisition, Mallinckrodt plc. will get access to Sucampo’s commercial asset AMITIZA, which is an effective drug for opioid-induced constipation in adult patients.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/202

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837